Jacobs Levy Equity Management’s Relmada Therapeutics RLMD Stock Holding History

Jacobs Levy Equity Management’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-45,602	Closed	-$23.7K	–	1178
2024 Q4	$23.7K	Sell	45,602 -112,070	-71%	-$273K	﹤0.01%	923
2024 Q3	$511K	Buy	157,672 +78,779	+100%	+$255K	﹤0.01%	829
2024 Q2	$237K	Sell	78,893 -47,023	-37%	-$170K	﹤0.01%	908
2024 Q1	$586K	Sell	125,916 -87,704	-41%	-$423K	﹤0.01%	802
2023 Q4	$884K	Buy	213,620 +87,774	+70%	+$260K	﹤0.01%	743
2023 Q3	$378K	Buy	+125,846	New	+$374K	﹤0.01%	849

Other funds holding RLMD

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

Jacobs Levy Equity Management's RLMD Position: Q1 2025 in Review

Jacobs Levy Equity Management sold out of Relmada Therapeutics (RLMD) in Q1 2025, closing a stake of 45,602 shares — an estimated $23.7K sold.

Jacobs Levy Equity Management first reported a position in RLMD in Q3 2023 and held it in 6 quarters. The position peaked at $884K in Q4 2023. 44 funds tracked by Wall St. Rank hold RLMD as of Q1 2025.

Jacobs Levy Equity Management reported no remaining Relmada Therapeutics position as of Q1 2025 after selling out during the quarter.
Jacobs Levy Equity Management sold 45,602 Relmada Therapeutics shares in Q1 2025, an estimated $23.7K.
Jacobs Levy Equity Management first reported a position in Relmada Therapeutics in Q3 2023 and held it in 6 quarters.
Jacobs Levy Equity Management's Relmada Therapeutics position peaked at $884K in Q4 2023.
44 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2025, filed 15 May 2025.